GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
1. Annett S, Moore G, Robson T. (2020) FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention. Pharmacol Ther, 215: 107623. [PMID:32622856]
2. Annett S, Moore G, Short A, Marshall A, McCrudden C, Yakkundi A, Das S, McCluggage WG, Nelson L, Harley I et al.. (2020) FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. Br J Cancer, 122 (3): 361-371. [PMID:31772325]
3. Barik S. (2018) Dual-Family Peptidylprolyl Isomerases (Immunophilins) of Select Monocellular Organisms. Biomolecules, 8 (4). [PMID:30445770]
4. Donley C, McClelland K, McKeen HD, Nelson L, Yakkundi A, Jithesh PV, Burrows J, McClements L, Valentine A, Prise KM et al.. (2014) Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen. Oncogene, 33 (26): 3441-50. [PMID:23912458]
5. Dunyak BM, Gestwicki JE. (2016) Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds. J Med Chem, 59 (21): 9622-9644. [PMID:27409354]
6. Edlich F, Erdmann F, Jarczowski F, Moutty MC, Weiwad M, Fischer G. (2007) The Bcl-2 regulator FKBP38-calmodulin-Ca2+ is inhibited by Hsp90. J Biol Chem, 282 (21): 15341-8. [PMID:17379601]
7. Edlich F, Lücke C. (2011) From cell death to viral replication: the diverse functions of the membrane-associated FKBP38. Curr Opin Pharmacol, 11 (4): 348-53. [PMID:21514222]
8. Erlejman AG, De Leo SA, Mazaira GI, Molinari AM, Camisay MF, Fontana V, Cox MB, Piwien-Pilipuk G, Galigniana MD. (2014) NF-κB transcriptional activity is modulated by FK506-binding proteins FKBP51 and FKBP52: a role for peptidyl-prolyl isomerase activity. J Biol Chem, 289 (38): 26263-26276. [PMID:25104352]
9. Frausto SD, Lee E, Tang H. (2013) Cyclophilins as modulators of viral replication. Viruses, 5 (7): 1684-701. [PMID:23852270]
10. Ghartey-Kwansah G, Li Z, Feng R, Wang L, Zhou X, Chen FZ, Xu MM, Jones O, Mu Y, Chen S et al.. (2018) Comparative analysis of FKBP family protein: evaluation, structure, and function in mammals and Drosophila melanogaster. BMC Dev Biol, 18 (1): 7. [PMID:29587629]
11. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A et al.. (2011) A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell, 20 (1): 79-91. [PMID:21741598]
12. Kolos JM, Voll AM, Bauder M, Hausch F. (2018) FKBP Ligands-Where We Are and Where to Go?. Front Pharmacol, 9: 1425. [PMID:30568592]
13. Koren 3rd J, Jinwal UK, Davey Z, Kiray J, Arulselvam K, Dickey CA. (2011) Bending tau into shape: the emerging role of peptidyl-prolyl isomerases in tauopathies. Mol Neurobiol, 44 (1): 65-70. [PMID:21523562]
14. Maestre-Martínez M, Haupt K, Edlich F, Jahreis G, Jarczowski F, Erdmann F, Fischer G, Lücke C. (2010) New structural aspects of FKBP38 activation. Biol Chem, 391 (10): 1157-67. [PMID:20707607]
15. McClements L, Annett S, Yakkundi A, O'Rourke M, Valentine A, Moustafa N, Alqudah A, Simões BM, Furlong F, Short A et al.. (2019) FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. BMC Cancer, 19 (1): 351. [PMID:30975104]
16. McClements L, Annett S, Yakkundi A, Robson T. (2015) The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases. Curr Mol Pharmacol, 9 (2): 165-79. [PMID:25986561]
17. McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne C, O'Rourke M, Young S, Scott CJ, McCarthy HO et al.. (2008) A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling. Endocrinology, 149 (11): 5724-34. [PMID:18669603]
18. Nath R. (2017) Peptidyl-prolyl isomerase (PPIase): an emerging area in tumor biology. Cancer Res Front, 3: 126–143. DOI: 10.17980/2017.126
19. Robson T, James IF. (2012) The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein. Drug Discov Today, 17 (11-12): 544-8. [PMID:22265918]
20. Saibil H. (2013) Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol, 14 (10): 630-42. [PMID:24026055]
21. Shirane M, Nakayama KI. (2003) Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol, 5 (1): 28-37. [PMID:12510191]
22. Storer CL, Dickey CA, Galigniana MD, Rein T, Cox MB. (2011) FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol Metab, 22 (12): 481-90. [PMID:21889356]
23. Sunnotel O, Hiripi L, Lagan K, McDaid JR, De León JM, Miyagawa Y, Crowe H, Kaluskar S, Ward M, Scullion C et al.. (2010) Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control study. Reprod Biol Endocrinol, 8: 22. [PMID:20210997]
24. Theuerkorn M, Fischer G, Schiene-Fischer C. (2011) Prolyl cis/trans isomerase signalling pathways in cancer. Curr Opin Pharmacol, 11 (4): 281-7. [PMID:21497135]
25. Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H et al.. (2011) FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin Cancer Res, 17 (5): 1044-56. [PMID:21364036]
26. Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO, Hirst DG et al.. (2013) The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway. PLoS One, 8 (2): e55075. [PMID:23457460]
27. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, Gu L, Tang X, Lu KP, Xiao ZX. (2002) The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature, 419 (6909): 849-53. [PMID:12397361]